Blood filter targets DNA to tame septic shock inflammation

NCT ID NCT07657767

Not yet recruiting Disease control Sponsor: Sergey Savko Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This trial tests a device called Nucleocore that removes cell-free DNA (cfDNA) from the blood of people with septic shock. High cfDNA levels are linked to severe inflammation and worse outcomes. The study enrolls adults aged 18-65 with septic shock and elevated cfDNA, and measures whether filtering the blood can reduce shock duration and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efferon CT plasma adsorption column (Nucleocore)
What this could lead to: If it works, this could provide a new way to treat septic shock by filtering out harmful DNA fragments that drive inflammation.
What could go wrong: This is an early-stage trial with only 60 participants, so results may not apply to all septic shock patients. The procedure carries risks from vascular access and blood filtering.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS

Contacts and locations

Locations

Moscow City Clinical Hospital named after S. S. Yudin

Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.